DOJ wants Anthem-Cigna bickering made public

The U.S. Justice Department (DOJ) may have new ammunition in their fight to keep Anthem and Cigna from merging: the companies’ own behind-the-scenes bickering.

The New York Times reported on a legal filing from the DOJ that alleges the in-house attorneys for both companies have exchanged letters accusing the other of violating the terms of the $48 million merger agreement. The DOJ is asking a federal judge to compel the insurers to release the letter, arguing they would “reveal the current state of hostility between defendants,” and call into question the insurers’ claims that the merger would save billions of dollars and improve care.  

“Such efficiencies don’t happen overnight,” the DOJ wrote in its court filing according to the Times. “They require cooperation over months (if not years) to integrate the operations of these multibillion-dollar firms.”

Both Anthem and Cigna declined to comment on the filing, though bickering between the insurers had been reported well before the DOJ sued to block the merger on antitrust grounds.

Anthem’s lawyers have hinted at the tension in court, saying a speedier trial schedule was needed, or else Cigna would exercise its right to back out of the merger beginning on April 30, 2017, collecting a $1.85 billion break-up fee in the process.

For more on DOJ’s filing and how the insurers’ disagreements could undermine their defense in the antitrust trial, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.